On the other hand, if the white blood cells continue to be adequate for continuation of therapy, then there is no role for
Neupogen/Neulasta. It would simply add
cost (to you and or your insurance company) and provide no real benefit. In these cases, if your white count were ever to drop low enough that the chemo would be dose reduced or delayed, the use of Neupogen would likely be commenced with the next dose and continued throughout treatment.